03 March 2026
03 March 2026
Participants received either oral fenebrutinib twice daily or oral teriflunomide once daily for at least 96 weeks.
LiCellGrow was developed to assist therapy developers in determining the optimal culture conditions during process development.
The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.
IDE study results at 24 months showed an 87.1% composite clinical success rate with the Synergy Disc.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
